ALLMedicine™ Guillain-barre Syndrome Center
Research & Reviews 258 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095850
The Canadian Journal of Neurological Sciences. Le Journal... Donaldson L, Margolin E
May 10th, 2022 - Variant Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination: Case Report and Review of the Literature.|2022|Donaldson L,Margolin E,|
https://doi.org/10.1093/ptj/pzac049
Physical Therapy; Masuccio FG, Tipa V et. al.
May 6th, 2022 - COVID-19 has been associated with neurological complications such as Guillain-Barre syndrome (GBS). Several cases have been reported, but without functional outcome data after intensive rehabilitation and medium-term follow-up. In this observation...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027043
BMC Neurology; Patel P, Shah D et. al.
Apr 24th, 2022 - The Guillain-Barre Syndrome (GBS), also known as acute idiopathic polyneuritis, is a critical acquired condition associated with preceding nonspecific infection or triggering factors like trauma, surgery, or vaccination. GBS is currently the most ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986226
Global Health Action; Wilder-Smith A, Brickley EB et. al.
Apr 5th, 2022 - Global health research partnerships with institutions from high-income countries and low- and middle-income countries are one of the European Commission's flagship programmes. Here, we report on the ZikaPLAN research consortium funded by the Europ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066502
The Neurologist; Aquino Ferraz LD, Marques NP et. al.
Mar 30th, 2022 - Assessment of Guillain-Barre Syndrome Cases in Brazil in the COVID-19 Era.|2022|Aquino Ferraz LD,Marques NP,Silveira DMM,de Magalhães MJS,Oliveira EA,|epidemiology,diagnosis,epidemiology,
Drugs 6 results see all →
Clinicaltrials.gov 4 results
https://clinicaltrials.gov/ct2/show/NCT05114941
Mar 16th, 2022 - Guillain-Barre syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy. The currently proven effective treatment methods include intravenous immunoglobulin and plasma exchange. In the clinical treatment process, the plasma so...
https://clinicaltrials.gov/ct2/show/NCT00004833
Apr 7th, 2015 - PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive either human immunoglobulin infusion (IVIg) (arm I) or plasmapheresis (arm II). Arm I patients receive liquid heat-treated IVIg for 4 days starting on da...
https://clinicaltrials.gov/ct2/show/NCT02029378
Sep 23rd, 2014 - Guillian-Barre Syndrome (GBS) is the most frequent cause of acute neuromuscular weakness in the Western World and can occur at any age. GBS is a rpadily progressive 'inflammatory' disorder of the perihperal nerves often leading to sever paresis of...
https://clinicaltrials.gov/ct2/show/NCT01516385
Jan 31st, 2012 - This research looks for markers in the blood of people with spinal cord injury that may be a sign of injury severity, or serve as a clue to the degree of recovery. Investigators would also like to compare the marker profile of these patient with t...
News 48 results
https://www.medscape.com/viewarticle/968599
Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...
https://www.medscape.com/viewarticle/962005
Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...
https://www.medscape.com/viewarticle/960777
Oct 14th, 2021 - NEW YORK (Reuters Health) - Data from the vaccine adverse event reporting system (VAERS) show a potential "small but statistically significant safety concern" for the development of Guillain-Barre syndrome (GBS) after receipt of the Janssen/Johnso...
https://www.mdedge.com/fedprac/article/246040/coronavirus-updates/delta-factor
Cynthia Geppert, MD, MA, MPH, MSBE
Sep 13th, 2021 - Several weeks ago, I received a call from my brother who, though not a health care professional, wanted me to know he thought the public was being too critical of scientists and physicians who “are giving us the best advice they can about COVID. P.
https://www.medscape.com/viewarticle/955233
Jul 23rd, 2021 - (Reuters) - Europe's medicines regulator said on Thursday it had added a nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's COVID-19 vaccine after it reviewed 108 cases reported worldwide....